FC

Franklin Covey Reports Strong Financial Results to Start Fiscal 2024

Retrieved on: 
Thursday, January 4, 2024

During the first quarter of fiscal 2024, AAP subscription revenue retention levels in the United States and Canada remained strong and were greater than 90%.

Key Points: 
  • During the first quarter of fiscal 2024, AAP subscription revenue retention levels in the United States and Canada remained strong and were greater than 90%.
  • Foreign exchange rates had an immaterial impact on the Company’s sales and operating results during the first quarter of fiscal 2024.
  • Operating Income: The Company’s income from operations for the first quarter of fiscal 2024 was $5.3 million, compared with $6.4 million in fiscal 2023.
  • On Thursday, January 4, 2024, at 5:00 p.m. Eastern (3:00 p.m. Mountain) Franklin Covey will host a conference call to review its fiscal 2024 first quarter financial results.

Representative complaints update

Retrieved on: 
Tuesday, January 2, 2024

Published: 13 December 2023

Key Points: 


Published: 13 December 2023
The OAIC has received multiple representative complaints following the major data breaches.
As at the date of publication, the Australian Information Commissioner (
AIC) has accepted two representative complaints; one against Medibank Private Limited in respect of its October 2022 data breach, the other against Singtel Optus Pty Limited in respect of its September 2022 data breach.

What is a representative complaint?

  • To make a valid representative complaint the requirements of sections 36 and 38 of the Privacy Act must be met.
  • This means that information gathered in the Medibank Commissioner-initiated investigation will be used for the purposes of the Medibank representative complaint.
  • Similarly, information gathered in the Optus CII will be used for the purposes of the Optus representative complaint.

Current court proceedings in respect of the representative complaints

Honda, Tokuyama, and Mitsubishi Corporation to Conduct Joint Demonstration of Decarbonizing Data Center Using By-product Hydrogen and Stationary Fuel Cell Power Station designed to Reuse Fuel Cell Systems from FCEVs

Retrieved on: 
Monday, December 25, 2023

TOKYO, Dec 25, 2023 - (JCN Newswire) - Honda Motor Co., Ltd. (Honda), Tokuyama Corporation (Tokuyama), and Mitsubishi Corporation (MC) ("Project Members") will conduct a joint demonstration to operate a data center using by-product hydrogen and a stationary fuel cell (FC) power station designed to reuse FC systems from fuel cell electric vehicles (FCEVs).

Key Points: 
  • TOKYO, Dec 25, 2023 - (JCN Newswire) - Honda Motor Co., Ltd. (Honda), Tokuyama Corporation (Tokuyama), and Mitsubishi Corporation (MC) ("Project Members") will conduct a joint demonstration to operate a data center using by-product hydrogen and a stationary fuel cell (FC) power station designed to reuse FC systems from fuel cell electric vehicles (FCEVs).
  • ("Demonstration Project").
  • Project Members will explore the potential of reusing automotive FC systems in a stationary application.
  • The objective of the Demonstration Project is to reduce the economic burden on customers installing and operating stationary FC systems, which will contribute to the decarbonization of the electric power.

Isuzu, Honda Begin Demonstration Testing Today of Fuel Cell-Powered Heavy-duty Truck on Public Roads in Japan

Retrieved on: 
Monday, December 25, 2023

TOKYO, Dec 25, 2023 - (JCN Newswire) - Isuzu Motors Limited and Honda Motor Co., Ltd. today began demonstration testing on public roads in Japan of the GIGA FUEL CELL, a fuel cell (FC)-powered heavy-duty truck currently being co-developed by the two companies.

Key Points: 
  • TOKYO, Dec 25, 2023 - (JCN Newswire) - Isuzu Motors Limited and Honda Motor Co., Ltd. today began demonstration testing on public roads in Japan of the GIGA FUEL CELL, a fuel cell (FC)-powered heavy-duty truck currently being co-developed by the two companies.
  • Through this demonstration testing, scheduled to run through September 2024, the two companies will continue making progress in collecting data, amassing knowledge and identifying technical issues in preparation for a 2027 market introduction.
  • The prototype model being used for this demonstration testing is the same type as the one exhibited at the Isuzu Group booth at the JAPAN MOBILITY SHOW 2023.
  • With the cooperation of Isuzu Logistics Co., Ltd. and Honda Logistics Inc., the logistics companies of Isuzu Group and Honda Group, respectively, demonstration testing of the GIGA FUEL CELL will be conducted on public roads in Japan to verify the potential of the utilization of hydrogen fuel and the practicality of FC trucks.

Butler Hall Capital LLC has issued an open letter to FC’s board of directors regarding opportunities to maximize shareholder value

Retrieved on: 
Friday, December 22, 2023

LOS ANGELES, Dec. 22, 2023 (GLOBE NEWSWIRE) -- A fund managed by Butler Hall Capital LLC (“Butler Hall”, “we”, or “our”) which owns shares of Franklin Covey Co. (“FC” or the “Company”), has issued an open letter to FC’s board of directors regarding opportunities to maximize shareholder value.

Key Points: 
  • Believes FC Should Initiate a Strategic Review for the Education Division, Which Could be Worth $200mm to a Strategic Buyer
    A Sale of the Education Division in Conjunction with a Significant Step-Up in Buybacks, Could Drive 50% Accretion to FC’s FCF/share and Yield a Stock Price of $83+
    LOS ANGELES, Dec. 22, 2023 (GLOBE NEWSWIRE) -- A fund managed by Butler Hall Capital LLC (“Butler Hall”, “we”, or “our”) which owns shares of Franklin Covey Co. (“FC” or the “Company”), has issued an open letter to FC’s board of directors regarding opportunities to maximize shareholder value.
  • A full copy of the letter is attached below and is available at:

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

Retrieved on: 
Saturday, December 9, 2023

The addition of ALLO-647 to standard lymphodepletion did not result in adverse events beyond those commonly observed with autologous CAR T cell therapy.

Key Points: 
  • The addition of ALLO-647 to standard lymphodepletion did not result in adverse events beyond those commonly observed with autologous CAR T cell therapy.
  • Neutropenia and anemia were the most common any-grade treatment-emergent adverse events (or TEAEs) and neutropenia, anemia, and thrombocytopenia were the most common Grade 3 or higher TEAEs.
  • Grade 3 or higher cytopenias decreased over time from Day 28 to Month 4 and were consistent across all subsets of patients.
  • Incidence of Grade 3 or higher cytopenias were consistent with that reported for autologous CAR T cell therapy.2-4

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Retrieved on: 
Thursday, December 7, 2023

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of enrollment for its Phase 1 clinical trial of XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab and reported updated monotherapy data from its ongoing Phase 1 clinical trial evaluating XTX101 in late-line patients with advanced and immuno-oncology (IO) refractory solid tumors. The data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on December 7, 2023.

Key Points: 
  • The data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on December 7, 2023.
  • XTX101 monotherapy was generally well-tolerated with treatment-related adverse events (TRAE) primarily Grade 1 or 2, and no patients discontinued treatment due to a TRAE.
  • In addition, as previously reported, no Grade 4 or 5 TRAEs were reported by investigators across all dosing levels and dosing intervals.
  • Xilio recently completed enrolling patients at the RP2D of 150 mg Q6W in monotherapy dose expansion and initiated enrollment in Phase 1 combination dose escalation to evaluate the safety, tolerability and efficacy of XTX101 in combination with atezolizumab.

Grupo Bimbo Signs Aitana Bonmatí, the World’s Best Soccer Player, to Boost Female Talent

Retrieved on: 
Tuesday, December 5, 2023

Aitana Bonmatí, FC Barcelona soccer player and Spanish National Soccer Team member, will be the global brand ambassador for BIMBO®️.

Key Points: 
  • Aitana Bonmatí, FC Barcelona soccer player and Spanish National Soccer Team member, will be the global brand ambassador for BIMBO®️.
  • HORSHAM, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Grupo Bimbo, the leading global bakery and current Global Partner of FC Barcelona and Main Partner of Female FC Barcelona, announced the addition of Spanish soccer player Aitana Bonmatí as a brand ambassador.
  • For a year, Grupo Bimbo has been a Global Partner of FC Barcelona and the Main Partner of Female FC Barcelona.
  • With initiatives like these, Grupo Bimbo continues to promote actions that allow us to nourish a better world.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Retrieved on: 
Tuesday, December 5, 2023

The trial will treat patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®).

Key Points: 
  • The trial will treat patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®).
  • “Patients with HER2-positive breast cancer who progress after Enhertu have few therapeutic options,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.
  • “BDC-1001 has a unique mechanism of action compared to available agents, mobilizing the patient’s immune system to fight cancer.
  • Title: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan.

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, November 29, 2023

NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr. Stavenhagen will lead the Company’s discovery and preclinical research and translational science initiatives.

Key Points: 
  • In this role, Dr. Stavenhagen will lead the Company’s discovery and preclinical research and translational science initiatives.
  • “I’m thrilled to welcome Jeff to the Dianthus team as we advance next-generation antibody therapeutics for patients living with severe autoimmune diseases.
  • He was most recently Chief Scientific Officer at Therini Bio, where he directed R&D initiatives leading to the development of a first-in-class monoclonal antibody for the treatment of neurodegenerative diseases.
  • She earned a master’s degree in biotechnology from Northwestern University and a bachelor’s degree in biology from the University of Iowa.